On-Demand: Development of Orally Delivered GLP-1 Therapeutics …From Diabetes to Obesity and Beyond

Dr. Andrew Lewis, Chief Scientific Officer, and Dr. Stuart Mair, Chief Medical Officer explore the latest developments in orally delivered GLP-1 agonists and take a look at potential future innovations. 

Our expert speakers examine obesity as a global health issue, discussing its profound impact on healthcare; guide us through the discovery of GLP-1 agonists and the potential for these therapeutics outside diabetes; and explore the challenges and potential solutions for orally-delivered GLP-1 products. 

You'll learn about:

• Drivers for oral incretin analogues and the CMC and clinical challenges in their development
• How Quotient Sciences' Translational Pharmaceutics® platform has enabled the accelerated development of both orally delivered peptides and small molecules in the incretin family
• Future innovation in GLP-1 agonists and oral peptides

Watch our on-demand recording and stay at the forefront of treatment advancements in this quickly evolving category.